tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Cardiomyopathy, Restrictive D002313 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Priapism D011317 1 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Intussusception D007443 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Retrognathia D063173 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Sheiner PA et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. 1994 Transplantation pmid:7513099
McCune TR et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. 1998 Transplantation pmid:9448150
Mentzer RM et al. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. 1998 Transplantation pmid:9448154
Burroughs TE et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. 2007 Transplantation pmid:17452891
Méndez A et al. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. 2014 Transplantation pmid:24492423
Fridell JA et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. 2006 Transplantation pmid:16906038
Misra S et al. Red cell aplasia in children on tacrolimus after liver transplantation. 1998 Transplantation pmid:9500636
Reutzel-Selke A et al. Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors. 2003 Transplantation pmid:12811235
Hougardy JM et al. The once-daily formulation of tacrolimus: a step forward in kidney transplantation? 2012 Transplantation pmid:22234346
Yasunami Y et al. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. 1990 Transplantation pmid:1691535
Metcalfe SM and Richards FM Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. 1990 Transplantation pmid:1691537
D'Antiga L et al. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. 2002 Transplantation pmid:11792983
Butani L et al. Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant recipient. 2002 Transplantation pmid:11793001
Ferraris JR et al. Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic rejection: changes in the immune responses. 2004 Transplantation pmid:15084930
Shapiro R et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. 1999 Transplantation pmid:10628763
Velidedeoglu E et al. Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. 2004 Transplantation pmid:15084934
Leung W et al. Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. 1999 Transplantation pmid:10385092
Andrés A et al. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. 2009 Transplantation pmid:19898206
McDiarmid SV et al. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. 1993 Transplantation pmid:7692636
Tabasco-Minguillan J et al. Insulin requirements after liver transplantation and FK-506 immunosuppression. 1993 Transplantation pmid:7692637
Guo Z et al. In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. 1997 Transplantation pmid:9075844
Xu X et al. FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. 2002 Transplantation pmid:12085010
Mueller AR et al. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. 1994 Transplantation pmid:7518974
Platz KP et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. 1994 Transplantation pmid:7518975
Sarwal MM et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. 2001 Transplantation pmid:11468528
Nobori S et al. Long-term acceptance of fully allogeneic cardiac grafts by cotransplantation of vascularized thymus in miniature swine. 2006 Transplantation pmid:16421473
Lang T et al. Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. 1996 Transplantation pmid:8824477
Luan FL et al. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. 2011 Transplantation pmid:21242885
Takatsuki M et al. Weaning of immunosuppression in living donor liver transplant recipients. 2001 Transplantation pmid:11502975
Shapiro R et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. 2008 Transplantation pmid:18431232
Meier M et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. 2006 Transplantation pmid:16612281
Panz VR et al. Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1. 2002 Transplantation pmid:11889436
Charney DA et al. Plasma cell-rich acute renal allograft rejection. 1999 Transplantation pmid:10515379
Fisher NC et al. The clinical impact of nephrotoxicity in liver transplantation. 2000 Transplantation pmid:10910259
Brunet M et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. 2006 Transplantation pmid:16495801
MacDonald AS Management strategies for nephrotoxicity. 2000 Transplantation pmid:10910262
Kessler L et al. Tacrolimus-associated optic neuropathy after pancreatic islet transplantation using a sirolimus/tacrolimus immunosuppressive regimen. 2006 Transplantation pmid:16495816
Moffatt SD and Metcalfe SM Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade. 2000 Transplantation pmid:10836388
Randhawa PS et al. Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization. 1999 Transplantation pmid:9921801
Higgins RM et al. Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. 2000 Transplantation pmid:10836393
Meiser BM The best dosing for initial tacrolimus application is trough level adapted! 2005 Transplantation pmid:15714162
Taylor-Fishwick DA et al. Evidence that rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use. 1993 Transplantation pmid:7689258
Hougardy JM et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. 2011 Transplantation pmid:21192316
Stevens C et al. The effects of immunosuppressive agents on in vitro production of human immunoglobulins. 1991 Transplantation pmid:1710843
Metcalfe S and Milner J Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. 1991 Transplantation pmid:1710844
Bayés B et al. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. 2004 Transplantation pmid:15257035
Miao G et al. Development of donor-specific immunoregulatory T-cells after local CTLA4Ig gene transfer to pancreatic allograft. 2004 Transplantation pmid:15257039
Wiesner RH A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. 1998 Transplantation pmid:9734494
Chan L et al. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. 2010 Transplantation pmid:20517177
Hodak SP et al. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. 1998 Transplantation pmid:9734501